Toronto-based Cedara introduced a new orthopedics desk application July 16. Earlier in the month, the company announced a deal with a major Chinese OEM to supply a user interface for its x-ray products. The good news came, however, on the heels of an
Toronto-based Cedara introduced a new orthopedics desk application July 16. Earlier in the month, the company announced a deal with a major Chinese OEM to supply a user interface for its x-ray products. The good news came, however, on the heels of an announcement that the company has been delisted from the Nasdaq effective July 7.
The newly released Cedara OrthoWorks is a suite of desktop and Web server software solutions designed for orthopedic surgeons. The product allows instant access to digital patient images, surgical planning aids, measurement tools, and a library of digital prosthetic templates.
The product release followed a July 7 announcement that Shan Dong XinHua Medical, one of the largest medical equipment manufacturers in China, will integrate its new x-ray systems with Cedara's I-Acquire DR universal acquisition console application. The Cedara technology allows the acquisition of images from multiple digital detectors and x-ray generators from a single user interface.
Cedara stock is now being traded on the OTC Bulletin Board in the wake of its delisting from the Nasdaq. The move became necessary when Cedara was not able to meet the minimum shareholders' equity requirement. The company's listing on the Toronto Stock Exchange, where most of its shares have historically traded, was not affected.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.